Antibacterial Agents TRIZ Cases

Heterocyclic compounds inhibit beta-lactamase enzymes, protecting antibiotics from degradation and restoring efficacy against resistant bacterial strains.

Carbamate glycolipid resolves cytokine balance issues by enhancing IFN-gamma while suppressing IL-4 for improved therapeutic efficacy.

Modifying pleuromutilin with a thioacetic acid side chain overcomes bacterial drug resistance while maintaining the core tricyclic diterpenoid skeleton.

Segmented pyridinium salt structures overcome multidrug-resistant tuberculosis strains while minimizing synthesis complexity.

KH-1-2 reduces intracellular bacterial load by 8 to 10 folds, addressing antibiotic resistance against Salmonella Typhi.

Adenoviral dodecahedron vector targets cancer cells through receptor binding, reducing adverse effects from systemic exposure.

Amphiphilic antimicrobial polymers segregate polar and nonpolar regions to disrupt bacterial membranes, treating resistant ophthalmic and otic infections.

Cation exchange resin isolates bioactive proteins from Manuka honey, resolving instability and low concentration issues.

Dual-specific antibodies bind IL-17A and IL-17F simultaneously, resolving incomplete inhibition from single antagonists.

Combining variant hepatitis C virus E1 and E2 glycoproteins into heterodimers induces broad-spectrum T-cell immunity against multiple viral genotypes.

Beta-lactamase activated prodrugs release metal chelators to starve resistant bacteria while sparing mammalian cells.

New pyrrolo[2,3-d]pyrimidin-2-one antimicrobials target resistant bacterial strains by inhibiting ribosomal function and protein synthesis.

N-fused bifunctional polypeptides link immune effectors to peptide-MHC binding partners via flexible linker sequences.

A non-irritating ophthalmic emulsion uses a composite surfactant system to stabilize oil particles below 1 µm.

Aqueous antimicrobial solution combines ε-polylysine and monoglycerol monolaurate with sucrose monolaurate to enhance solubility.

A purified bacterial mixture colonizes the gut microbiome to modulate bile acid profiles and short-chain fatty acid levels.

Whey protein micelles delay gastric emptying to sustain plasma amino acid levels, countering the short duration of conventional proteins.

Biodegradable intraocular implants sustain prostamide release to manage ocular hypertension while eliminating frequent topical administration.

A unitary nacelle structure integrates a composite fan housing to transfer loads directly to the support member.

Platelet membrane coatings on synthetic cores resolve immunogenicity trade-offs by enabling pathogen binding while avoiding foreign material exposure.

Trehalase enzymes hydrolyze trehalose to dismantle the biofilm matrix, enabling antimicrobial penetration and reducing treatment frequency.

Combining PspA variants with PlyL460D overcomes short immune response duration in infants by establishing T-cell memory.

Recombinant lactoferrin interferes with quorum sensing pathways, preventing biofilm formation and reducing antibiotic resistance in recurrent infections.

Proline, alanine, and glycine buffers stabilize recombinant anthrax protective antigen against aggregation during prolonged storage.

Recombinant human CC10 reduces sinus pain and polyp growth without conventional medication side effects.

Segmenting thalidomide into specific enantiomers reduces teratogenicity while maintaining anti-angiogenic activity.

A pharmacological association of N-acetylcysteine and colistin disrupts bacterial biofilms to restore antibiotic susceptibility.

Specific CpG motifs activate avian TLR21, resolving low efficacy in non-mammalian species.

Direct-fed microbials replace antibiotics to reduce food supply contamination while maintaining microbial balance.

Cyclopentyl-substituted triazolo(4,5-d)pyrimidine derivatives resist bacterial growth and biofilm formation on medical devices to address antibiotic resistance.

Small molecule inhibitors block the p53-MDM2 interaction to restore tumor suppressor activity in cancer cells.

4′-O-substituted isoindoline derivatives inhibit angiogenesis and TNF-α cytokines to treat cancer while reducing toxicity and side effects.

Isolated outer membrane vesicles from PorA-PorB deficient strains deliver cross-protective antibody responses against serogroup B and gonococcal infections.

Compounds targeting the ATP binding site and DFG-in pocket inhibit multiple kinases to treat proliferative diseases.

Modifying carbapenem structures via parameter changes and composite materials overcomes antibiotic resistance in Acinetobacter baumannii infections.

N-sulfonyl homoserine lactone derivatives modulate bacterial communication pathways to regulate virulence gene expression in Gram-negative pathogens.

Secologanic acid in honeysuckle extract reverses bacterial resistance, restoring antibiotic sensitivity for treating refractory infections.

Merging Formula I compounds with aminoglycosides or glycopeptides overcomes bacterial resistance and eradicates biofilms.

Regulated delayed lysis of attenuated Salmonella adjuvants stimulates innate immunity while preventing excessive inflammation and strain persistence.

VraSR operon inhibitors potentiate beta-lactam antibiotic activity against Staphylococcus aureus infections.

Synthetic glycan antigens linked to carrier proteins stimulate targeted immune responses against Pseudomonas aeruginosa infections.

Formula I compounds inhibit spore germination and outgrowth, reducing relapse rates without disrupting the gut microbiome.

Novel cyclic lipodepsipeptides deliver potent antibacterial activity against priority pathogens through targeted peptide synthesis.

Antibodies bind hepcidin epitopes to neutralize activity, resolving iron refractory anemia by blocking hepcidin interaction with ferroportin.

Immunomodulatory compounds suppress regulatory T cells to enhance cell-mediated immunity without triggering allergic reactions.